Ube Industries, Inc.

Sankyo Company, Limited

Daiichi Sankyo Company, Limited

Kenji Yoneda

Koji Ito

Masahiko Hagihara

Noriaki Iwase

Katsunori Takata

Tomoko Kanda

Tomio Kimura

Hiroyuki Koike

Teruhiko Inoue

Tsuyoshi Nakamura

Shigeru Ushiyama

Tetsushi Katsube

Fumitoshi Asai

Hidenori Namiki

Atsuhiro Sugidachi

Ken-ichi Komori

Hidetoshi Sunamoto

Yusuke Shiraishi

Eiji Okanari

Nobuhiko Shibakawa

Ryo Iwamura

Satoshi Umezaki

Yasunori Tokunaga

Naoki Terasaka

Jun-ichiro Kita

Haruka Yamada

Manabu Shigetomi

Osamu Kikuchi

Toshihiko Ikeda

Kazunari Tsuboike

Akiko Shima

Naoya Kinoshita

Kiyoshi Yamamoto

The present invention provides a compound that is highly safe and useful in the prevention, alleviation, and/or treatment of various diseases involving enteropeptidase inhibition and/or trypsin inhibition, a pharmaceutical composition containing the compound, a method for producing the compound, and the like. Specifically, the present invention provides a compound represented by the following general formula (I): [wherein: Aand Aeach independently represent an inhibitor residue having at least one activity selected from an enteropeptidase inhibitory activity and a trypsin inhibitory activity; and Z represents a spacer that links Ato A] or a pharmaceutically acceptable salt thereof.

Double-headed protease inhibitor

The present invention provides a substituted biaryl compound of general formula (I): 

Substituted biaryl compound

The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein Ris H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.

Substituted pyridine compound

The present invention is to provide a medical composition for the treatment or prophylaxis of glaucoma which comprises a pyridylaminoacetic acid compound represented by the formula (1): wherein R, R, R, Y, and Z are defined in the specification.

Medical composition for treatment or prophylaxis of glaucoma

A cyclic amine derivative represented by the following formula: ##STR1## wherein R.sup.1 represents a substituted or unsubstituted phenyl group, R.sup.2 represents a substituted of unsubstituted C.sub.1 -C.sub.8 aliphatic acyl group, a substituted or unsubstituted benzoyl group or a C.sub.1 -C.sub.4 alkoxycarbonyl group, and R.sup.3 represents a substituted 3 to 7 membered saturated cyclic amino group which may form a fused ring; or pharmaceutically acceptable salts thereof. The compounds and salts have excellent platelet aggregation inhibitory action. They are useful for the treatment and prevention of such diseases as embolism, thrombosis or arteriosclerosis and for the preparation of pharmaceutical compositions for such uses.

Cyclic amine derivatives

Growing community of inventors

Ube, Japan

Kenji Yoneda